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Kynurenine 3-monooxygenase (KMO) is an enzyme central to the kynurenine pathway of tryptophan
metabolism. KMO has been implicated as a therapeutic target in several disease states, including Hun-
tington’s disease. Recombinant human KMO protein production is challenging due to the presence of
transmembrane domains, which localise KMO to the outer mitochondrial membrane and render KMO
insoluble in many in vitro expression systems. Efﬁcient bacterial expression of human KMO would accel-
erate drug development of KMO inhibitors but until now this has not been achieved. Here we report the
ﬁrst successful bacterial (Escherichia coli) expression of active FLAG™-tagged human KMO enzyme
expressed in the soluble fraction and progress towards its puriﬁcation.
 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
In mammals, the kynurenine pathway is the route of 99% of
dietary tryptophan metabolism and is the primary route of
synthesis of the essential cellular cofactor nicotinamide adenine
dinucleotide (NAD)1 [1,2]. Kynurenine metabolism produces several
biologically-active intermediates with diverse physiological actions
which participate in the pathogenesis of various neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease [3] and sterile systemic inﬂammation [4,5].
The kynurenine pathway has an established mechanistic role in
immune regulation [6].Central to the kynurenine pathway is the NADPH-dependant
ﬂavoprotein hydroxylase, kynurenine 3-monooxygenase (KMO)
(EC 1.14.13.9) (Fig. 1). This enzyme catalyses the speciﬁc hydroxyl-
ation of kynurenine (L-Kyn) at the 3 position of its phenol ring to
generate 3-hydroxykynurenine (3-HK) [3]. KMO protein is mono-
meric and has a molecular mass of 50 kDa with 1 mol of non-
covalently bound ﬂavin adenine dinucleotide (FAD) per mol of
protein monomer [7]. FAD is very tightly bound to KMO and is slow
to dissociate [8]. The protein has been shown to undergo post-
translational modiﬁcation when expressed in mammalian cells
and three N-glycosylation sites have been identiﬁed [8]. KMO is
contained within macrophage and microglial cells, with low KMO
levels distributed throughout all regions of the brain and high lev-
els found in the liver and kidney [3]. The enzyme is believed to be
localised to the outer mitochondrial membrane due to the pres-
ence of a proposed transmembrane domain near its C-terminus
[9]. 3-HK, the product of KMO catalysis, exhibits toxicity to cells
through reactive oxygen species generation, the cross-linking of
proteins and mitochondrial respiratory chain inhibition [10].
KMO has recently been implicated as a therapeutic target for both
Huntington’s disease [11] and post-traumatic sepsis [4].
Currently, there are no successful reports of bacterially
expressed human KMO protein in the scientiﬁc literature and con-
sequently no crystal structure is available for the human enzyme.
Fig. 1. Kynurenine pathway. Biochemical pathway of tryptophan breakdown, KMO highlighted by blue box (adapted from Crozier-Reabe, 2008 [10]). (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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in a mammalian expression system and demonstrated a Km of
153 and 100 lM for substrates NADPH and kynurenine respec-
tively [8]. Puriﬁcation of the rat (Rattus norvegicus) [12] and
bacterial (Pseudomonas ﬂuorescens) [13] enzymes has been demon-
strated. Rat KMO has high sequence homology with human KMO,
but P. ﬂuorescens KMO exhibits low sequence homology when
compared with the human enzyme. More recently expression of
human KMO in insect cells has been reported, however, problems
due to low yields and poor stability were described and the purity
of the protein was not indicated or the enzyme characterised [14].
The crystal structure of Saccharomyces cerevisiae KMO has recently
been reported [14]. It is believed that the active site residues iden-
tiﬁed in the yeast KMO crystal structure are virtually identical in
human KMO [14]. However, human KMO has a region of hydropho-
bic amino acids at the C-terminus, believed to be the mitochondrial
membrane anchoring domain, which is required for enzymatic
activity and is also thought to contribute to the low aqueous solu-
bility of the protein [8]. It should be noted that the protein con-
struct used to obtain the yeast KMO crystal structure was a
truncated version of the enzyme which did not contain the equiv-
alent membrane targeting domain [14]. Importantly, targetted
truncation experiments on the pig KMO enzyme show that the
hydrophobic C-terminus has a dual role, participating in mem-
brane anchoring and enzymatic activity [15]. It is recognised that
pig KMO appears to form protein-protein complexes with two
other outer mitochondrial membrane proteins: cytochrome b5
and monoamine oxidase subunit B. Uemera et al [7] found removal
of these contaminants without losing enzymatic activity to be
challenging, suggesting that KMO requires a membranous environ-
ment for efﬁcient folding and function.The FLAG™-tag is a polypeptide (DYKDDDDK) with several uses
in recombinant protein production. The epitope can be utilised for
isolation of fusion proteins by afﬁnity chromatography and speciﬁc
recognition by commercially available antibodies [16]. Because the
FLAG peptide tag is hydrophilic, it is exposed and accessible on the
surface of the fusion protein, and the fusion partner portion is less
likely to be functionally altered [16]. FLAG tags can be multiplexed
to enhance epitope speciﬁcity, for example, the 3FLAG tag con-
tains three consecutive FLAG sequences.
Our aim in this work was to express functional human KMO in a
bacterial expression system and to optimise solubility and puriﬁca-
tion with the use of cleavable fusion protein tags.Materials and methods
Gene synthesis and cloning
Codon-optimised synthetic genes were prepared by Genscript
and provided in the vector pUC57.Truncated KMO (trKMO)
A codon-optimised synthetic gene consisting of the codons for
amino acids 1-385 of human KMO was prepared as above with
an NdeI restriction site incorporated at the 50-end and a NotI
restriction site at the 30-end. The gene was removed from vector
pUC57 by restriction digest with NdeI and NotI and ligated into
the vector pET24b (Novagen) for expression in Escherichia coli
(Fig. 2A). The truncated gene was customised without a stop codon
to allow incorporation of a C-terminal 6 polyhistidine tag con-
tained within the pET24b vector.
Fig. 2. Protein construct drawings. Cartoon illustrating the composition of each protein construct, (A) truncated hKMO-6 His; (B) full-length hKMO-6His; (C) full length
hKMO-12His-3FLAG.
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The full length gene (GenBank Accession No. NM_003679) (Arg
452 variant) was prepared as above with an NdeI restriction site at
the 50-end and a NotI restriction site at the 30-end (the alternative
Cys 452 polymorphic variant was not prepared). The gene was
removed from vector pUC57 by restriction digest with NdeI and
NotI and ligated into the vector pET24b (Novagen) for expression
in E. coli (Fig. 2B). The full length gene was customised without a
stop codon to allow incorporation of a C-terminal 6 polyhistidine
tag contained within the pET24b vector.
Full length KMO-12His-FLAG (KMO-FLAG)
For expression as a FLAG tagged gene, the full length gene (Arg
452 variant) was designed with sequences encoding a 12 poly
histidine tag (CATCATCACCATCACCATCATCATCACCATCACCAT),
TEV protease site (GAAAACCTGTATTTTCAGGGT) and 3FLAG
epitope (ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGA-
TATCGATTACAAGGATGACGATGACAAGTGA) at the 30-end of the
KMO gene. The gene incorporated a NheI restriction site at
the 50-end and a NotI restriction site after the stop codon at the
30-end. The gene was removed from pUC57 and ligated into the
vector pET24b (Fig. 2C.).
Bacterial cell expression
Truncated KMO
Truncated KMO was expressed in the E. coli cell strain
BL21(DE3) pLysS (Invitrogen, C606010). Bacterial cells transformed
with the pET24b-trKMO plasmid were grown in LB broth with anti-
biotics kanamycin (Sigma Aldrich, 60615) and chloramphenicol
(Sigma Aldrich, C0378) at 37 C with shaking at 250 rpm until
the optical density at 600 nm was 0.8. Cells were then induced
with 1 mM Isopropyl b-D-1-thiogalactopyranoside (IPTG) (Sigma
Aldrich, I5502) for 4 h at 37 C. Bacterial cells were collected by
centrifugation at 6000 rpm for 10 min at 4 C. Cell pellets were fro-
zen at 20 C until preparation of cell free extract.
Full length KMO-6His (ﬂKMO) and KMO-12His-FLAG
Full length and KMO-FLAGwere expressed as above with induc-
tion at 18 C for 16 h. Bacterial cells were collected by centrifuga-
tion at 6000 rpm for 10 min at 4 C. Cell pellets were frozen at
20 C until preparation of lysate.
Validation of expression
Lysed bacterial cell expression samples were examined by SDS-
PAGE with simplyblue (Invitrogen, LC6060) staining and analysed
by Western blot. Anti-His(C-term)-HRP antibody (Invitrogen,
R931-25) (1:2000 dilution) was used to detect the truncate and
ﬂKMO proteins, and anti-FLAG M2 antibody (Sigma Aldrich,F1804) (1:1000) with goat anti-mouse HRP conjugate secondary
antibody (Abcam, ab6832) (1:10000) was used to detect KMO-
FLAG protein.
Activity assay
Standard protein assay procedure using bio-rad reagent
(Bio-Rad, 500-0006) and BSA protein standards (Sigma Aldrich,
P0914-10AMP) were used to determine the total protein concen-
tration in the cell free extract. Cell free extracts were analysed
for KMO enzymatic activity by measuring the conversion of
L-Kyn to 3-HK detected by liquid chromatography–mass spectrom-
etry (LC–MS/MS) in a protocol similar to that reported by Courtney
et al [17]. 200 lg Total protein was incubated in 4 mM MgCl2
(Melford, M0533), 1 mM NADPH (Sigma Aldrich, N5130) and
200 lM L-Kynurenine (Sigma Aldrich, K8625) in 20 mM HEPES,
pH7 for 2 h at 37 C with gentle shaking at 250 rpm in a total assay
volume of 100 ll. Assay samples were added to 500 ll acetonitrile
(VWR, 200.60.320) with 25 lg/ml d5 Trp (Sigma Aldrich, T9753)
(internal standard) to terminate activity and centrifuged at
4000 rpm for 20 min to pellet the precipitate. The supernatant
was removed and dried under nitrogen and the residue
re-suspended in 30:70 methanol:water with 0.1% formic acid for
LC–MS/MS analysis.
For the determination of steady state kinetic parameters for the
substrate L-Kynurenine, NADPH was added at a concentration of
2 mM with glucose-6 phosphate (Sigma Aldrich, G7879) (2 mM)
and glucose-6 phosphate dehydrogenase (Sigma Aldrich, G6378)
(1 unit per assay) to maintain the NADPH concentration. L-Kynu-
renine was added at concentrations of 2, 1, 0.5, 0.25, 0.125,
0.062, 0.031, 0.015 mM. For co-factor NADPH dependence of the
enzymatic activity, L-Kynurenine was added in excess at a concen-
tration of 500 lM. NADPH was added at a concentration of 100, 50,
25, 12.5, 6.2, 3.1, 1.5, 0.75 lM. In each case assays were performed
in duplicate.
LC–MS analysis was carried out using the TSQ Quantum Discov-
ery triple quadrupole mass spectrometer (Thermo Fisher Scientiﬁc,
Hemel Hempstead, UK). The column used was a pentaﬂuorophenyl
(PFP) fused pore column, the column temperature was set at 40 C.
The injection volume was 10 ll and the ﬂow rate was 500 ll/min.
The method had a run time of 4 min and d5 Tryptophan was used
as an internal standard. Qualiﬁer and quantiﬁer peaks were identi-
ﬁed for 3-HK and for d5 Tryptophan. Data was acquired and pro-
cessed using Xcalibur 1.4 and LC Quan 2.0 SP1 software packages.
Membrane protein isolation protocol
Full length KMO-6His
Bacterial cell pellet containing expressed ﬂKMO was thawed
and re-suspended in 20 mM HEPES pH 7, 1 mM DTT (Sigma
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100 (Sigma Aldrich, X100) and EDTA-free protease inhibitors
(Roche, 04693116001). Cells were lysed by sonication and centri-
fuged for 40 min at 20,000 rpm at 4 C. Samples of all pellet and
supernatant fractions were retained at each step of the protocol.
The soluble fraction (supernatant) was centrifuged for 1 h at
100,000 rpm at 4 C and the resultant supernatant was named sol-
uble fraction 1 and the pellet named insoluble pellet 1. Insoluble
pellet 1 was passed through a 24-gauge needle to emulsify the
sample, then incubated with 1% Triton-X 100 for 1 h at 4 C with
agitation. The sample was centrifuged for another hour at
100,000 rpm at 4 C resulting in soluble fraction 2 and emulsiﬁed
pellet 1before repetition of the emulsiﬁcation/solubilisation step
on emulsiﬁed pellet 1. One further centrifugation step allowed
extraction of soluble fraction 3 and emulsiﬁed pellet 2. Each pellet
and supernatant sample was assayed for KMO enzymatic activity
to determine the location of the protein at each stage of the
protocol.
Solubilisation with detergent
To improve the solubility of cell lysate preparations, various
detergents were used as follows.
Full length KMO-6His
Bacterial cells were thawed, re-suspended and lysed as before.
The crude lysate was incubated with detergents DDM (Sigma
Aldrich, D4641), C12E8 (Sigma Aldrich, P8925), Triton-X 100,
Tween20 (Sigma Aldrich, P1379), CHAPS (Sigma Aldrich, P9426)
and sarkosyl (Sigma Aldrich, L9150) separately at a ﬁnal concentra-
tion of 1% and incubated for up to 4 h at 4 C with agitation. Lysates
were then centrifuged at 20000 rpm for 40 min at 4 C. Denaturing
treatment was also carried out using 6 M guanidine hydrochloride
(GuHCI), 50 mM DTT and separately, 10 M urea, 50 mM DTT under
the same conditions as the detergent screen. Pellet and superna-
tant fractions were run out on an SDS–PAGE protein gel (Invitro-
gen, NP0322BOX) with simplyblue staining and analysed by
Western blot to detect the protein and determine its solubility.
Protein puriﬁcation
Truncate KMO
The bacterial cell pellet was thawed and re-suspended in
20 mM HEPES pH7, 200 mM NaCl (Sigma Aldrich, S9888), 10 lM
FAD (Sigma Aldrich, F6625) with EDTA-free protease inhibitors.
Cells were lysed by sonication and centrifuged to pellet cell debris
as above. The soluble supernatant fraction was puriﬁed on a 5 ml
HisTrap ff crude column (GE Healthcare, 17-5286-01) using the
AKTA protein puriﬁcation system (GE Healthcare). The column
was washed with ten column volumes of 20 mM HEPES pH7,
200 mM NaCl and 25 mM imidazole (Sigma Aldrich, I5513). Bound
protein was eluted from the column using 20 mM HEPES pH7,
200 mM NaCl and 1 M imidazole. The fractions corresponding to
each peak in the chromatogram were combined and dialysed over-
night against buffer containing 20 mM HEPES pH7 and 10 lM FAD.
The dialysed sample was analysed by SDS–PAGE to determine pur-
ity and Western blot analysis was used to identify the truncated
KMO protein.
Full length KMO-12His-FLAG
The bacterial cell pellet was thawed and re-suspended in
20 mM HEPES pH7, 10 lM FAD with EDTA-free protease inhibitors.
Cells were lysed by sonication and centrifuged to pellet cell debris.
Protein A magnetic beads (Millipore, LSKMAGA02) were conju-
gated to anti-FLAG M2 antibody (Sigma Aldrich) by incubation at
room temperature for forty minutes with agitation. Beads werethen washed with phosphate-buffered saline (PBS) + 0.1% Tween20
before incubating with the soluble supernatant fraction for 2 h at
4 C with shaking. The bead-antibody-protein complexes were
then isolated using a magnet and the beads washed twice before
re-suspending in 20 mMHEPES pH7, 10 lM FADwith TEV protease
(Sigma Aldrich, T4455) at a ratio of 1:100 of target protein for 4 h
at 4 C. After removal of the beads by magnet, the supernatant was
injected onto a GSTrap HP 1 ml column (GE Healthcare, 17-5281-
01) to remove GST-tagged TEV protease from the sample. The ﬂow-
through sample containing the KMO-12His protein was dialysed
overnight against 20 mM HEPES pH7, 10 lM FAD buffer. The dia-
lysed sample was analysed by SDS–PAGE to determine purity
and Western blot analysis was used to identify KMO-12His protein
(anti-His(C-term)-HRP Ab at 1:2000 dilution).
Protein identiﬁcation
Puriﬁed samples were separated using SDS–PAGE and stained
with simplyblue before the desired bands were excised from the
gel and sent to the Scottish instrumentation and resource centre
for advanced mass spectrometry (SIRCAMS) Facility at the Univer-
sity of Edinburgh for identiﬁcation by mass peptide ﬁngerprinting.
The bands were digested by in-gel tryptic digest and the proteins
separated by reverse phase chromatography. Peptide fragmenta-
tion data was matched against a protein database using the MAS-
COT search engine.
Real time-PCR
Full length KMO-FLAG was expressed in BL21 (DE3) pLysS com-
petent cells as before. Non-transformed wild type cells were used
as a control. Total RNA was extracted from cell pellets using an
RNeasy Mini kit (Qiagen, 74104). 1 lg of total RNA was used for
ﬁrst strand cDNA synthesis using a QuantiTect Reverse Transcrip-
tion Kit (Qiagen, 205310). Expression of the tryptophan synthase
subunit beta (TSSB) gene was determined by real-time PCR. The
PCR primers were designed according to published E. coli ‘BL21
(DE3) pLysS’ genome sequences (GenBank: CP001665.1). Ampliﬁ-
cation of cDNA samples was carried out using power SYBR green
PCR master mix (AB Applied Biosystem, 4309155) under the fol-
lowing conditions: 10 min denaturation at 95 C, 45 cycles of
15 s at 95 C and 1 min at 60 C. This was followed by product
melting to conﬁrm single PCR products. Thermal cycling and ﬂuo-
rescence detection were conducted in a StepOne real time PCR sys-
tem (AB Applied Biosystem). All reactions were carried out in
triplicate and the cycle threshold (Ct) number of the targeted gene
in each sample was obtained.Results
Enzyme activity of full-length KMO-6His is restricted to the insoluble
fraction
Expression of the full length KMO protein was apparent in the
insoluble fraction as shown by the 55 kDa band on the SDS–PAGE
gel (Fig. 3A). KMO was found to account for 15.5% of the total pro-
tein in the insoluble fraction as estimated by gel analysis using
ImageJ software. Following Western blot analysis of soluble and
insoluble fractions, a comparatively small quantity of protein was
found to be soluble (Fig. 3B). Attempts to solubilise the enzyme
using various detergents and denaturing agents were not success-
ful. In a kinetic assay measuring KMO activity in each fraction by
the production of 3HK, KMO activity correlated with protein
expression levels in soluble and insoluble fractions, with signiﬁ-
cant KMO enzymatic activity demonstrated in the insoluble pellet
Fig. 3. Insoluble ﬂKMO. (A) SDS-PAGE protein gel stained with simplyblue. Lane 1.
Soluble fraction following over-expression of full length KMO in bacterial cells. Lane
2. Insoluble fraction, KMO protein (55 kDa) highlighted by arrow. (B) Western blot
of the same samples, chemiluminescence detection using Anti-His(c-term)-HRP
antibody. Lanes as before. The majority of the KMO protein is present in the
insoluble fraction. (C) Cartoon illustrating the ﬂKMO-6His construct. (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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eral emulsiﬁcation and centrifugation steps indicating that KMO
protein is membrane/protein associated (Table 1).
The small quantities of protein found in the soluble fraction did
not bind to NiNTA afﬁnity or ion exchange chromatography resin.C-terminal truncates of huKMO are soluble but enzyme activity is lost
C-terminal truncated KMO protein was readily expressed in the
soluble fraction. The soluble enzyme was puriﬁed by NiNTA afﬁn-
ity chromatography as indicated in Fig. 4A. However, soluble trun-
cated KMO protein did not demonstrate enzymatic activity in a
crude bacterial cell lysate or puriﬁed form as indicated by no pro-
duction of 3-HK. The identity of the puriﬁed 44 kDa protein band
was determined by mass peptide ﬁngerprinting to be human kyn-
urenine 3-monooxygenase (Table 2).Full length huKMO-12His-FLAG is soluble and active
Expression of soluble FLAG tagged KMO was indicated by a
57 kDa band on an SDS-PAGE gel and validated by Western blotTable 1
Membrane associated KMO. Membrane protein isolation protocol samples show that
KMO activity is signiﬁcantly higher in the insoluble pellet fractions indicating that
KMO is membrane/protein associated.
Sample Total protein assayed (lg) 3-HK produced (lM)
Soluble fraction 1 200 1.4
Soluble fraction 2 200 7.6
Insoluble pellet 1 200 79.7
Emulsiﬁed pellet 1 200 68.7
Soluble fraction 3 200 None detected
Emulsiﬁed pellet 2 200 160.2(Fig. 5A). Enzymatic activity of the protein expressed in the soluble
fraction was indicated by signiﬁcant 3-HK production.
Puriﬁcation
Partial puriﬁcation was achieved using afﬁnity chromatography
on anti-FLAG M2 antibody conjugated protein A magnetic beads
(Fig. 5B). KMO was found to account for 71% of the total protein
remaining after puriﬁcation as determined by gel analysis using
ImageJ software. This partially puriﬁed fraction contained 1.8 mg
total protein meaning that 19% of recombinant KMO was recov-
ered from the soluble fraction. The SDS-PAGE gel indicates that
puriﬁed KMO protein (57 kDa) co-puriﬁes with two other protein
bands. These proteins were identiﬁed as E. coli proteins tryptophan
synthase beta subunit and a putative GTP binding protein by mass
peptide ﬁngerprinting (Table 3). Real Time-PCR results showed no
signiﬁcant difference in expression of tryptophan synthase beta
subunit mRNA between BL21(DE3) pLysS cells expressing KMO-
FLAG and wild type control cells. The RQ value for the control cells
was set at one for comparative purposes and the measured RQ
value for pLysS cells expressing KMO-FLAG was 0.72.
Kinetic characterisation
Previous studies have shown that it is possible to monitor
NADPH oxidation by absorbance to measure KMO activity. How-
ever, this assay is insensitive and requires higher levels of puriﬁed
protein. Since the level of KMO expression was low we used an
LC–MS/MS assay for the accurate determination of steady state
kinetic parameters. For all assays turnover of kynurenine in this
stopped kinetic assay was in the linear range thus allowing accu-
rate measurement of the initial reaction velocities to ﬁt the Km
for each substrate. Full length KMO-6His demonstrated a Km for
L-Kynurenine of 148.6 ± 20.5 lM and a Km for NADPH of
6.8 ± 1.2 lM (Fig. 6). Puriﬁed full length KMO-12His (FLAG tag
removed during afﬁnity puriﬁcation) was found to have a Km for
L-Kynurenine of 153 ± 30 lM and a Km for NADPH of 8.7 ±
1.6 lM. Steady state kinetic data were plotted using GraphPad
Prism version 4.0 and the data was ﬁtted to the Michaelis–Menten
equation (v = Vmax.[L-Kyn]/(Km + [L-Kyn]). (Fig. 6). Expression
parameters for all three protein constructs are summarised in
Table 4.Discussion
Human KMO is a drug development target of increasing impor-
tance. Here, we report the ﬁrst successful expression of huKMO in a
bacterial expression system and describe the partially puriﬁed,
FLAG-tagged recombinant human enzyme expressed in E. coli.
Full-length 6 histidine tagged human KMO protein demonstrated
signiﬁcant expression but remained predominantly in the insolu-
ble fraction. The comparatively smaller quantity of protein found
in the soluble fraction did not demonstrate afﬁnity for NiNTA or
cation exchange chromatography resin despite the 6xhistidine
tag and net positive charge. The putative mitochondrial mem-
brane-targeting C-terminal domain may be responsible for protein
insolubility [9]. The amount of KMO in the soluble fraction was not
improved by membrane protein isolation and detergent solubilisa-
tion techniques. It is reasonable to assume that huKMO localises to
the pellet fraction at each step of the membrane protein isolation
protocol because it is membrane-protein associated in vivo. KMO
was not successfully extracted from the pellet fraction at any stage,
despite exhaustive efforts, indicating formation of very tightly
bound aggregates. Membrane or protein association could explain
the inaccessibility of the protein for puriﬁcation by afﬁnity chro-
matography. Despite the insoluble and aggregated state of this
construct, the protein did demonstrate KMO enzymatic activity.
Fig. 4. Puriﬁed trKMO. (A) Chromatogram produced during NiNTA afﬁnity puriﬁcation of truncate KMO. (B) SDS-PAGE protein gel stained with simplyblue showing HisTrap
puriﬁcation of truncated human KMO protein, (a) Cell-free extract prior to afﬁnity chromatography, (b) ﬂowthrough proteins which did not bind to the column, (c) ﬁrst
column wash, (d) second column wash, (e) third column wash, (f) pure truncated human KMO protein (44 kDa) from the fractions under the chromatogram. (C) Cartoon
illustrating the trKMO construct. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Positive KMO ID. Mass peptide ﬁngerprinting results identiﬁed the puriﬁed protein
gel band as KMO. A probability based Mowse score above 50 is acceptable as identity.
Protein ID Mowse score
Human kynurenine 3-monooxygenase 535
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native state, a membranous environment may be desirable for
the activity of the recombinant enzyme.
In an attempt to improve solubility of the human enzyme, a
truncated construct was created which lacked the coding sequenceFig. 5. Soluble partially puriﬁed KMO-FLAG. (A) Western blot using chemiluminescence
soluble fraction from over-expressed KMO-12His-FLAG (57 kDa) in bacterial cells. (B)
magnetic bead puriﬁcation of KMO-12His-FLAG, (a) Cell-free extract prior to puriﬁcation
wash, (d) second bead wash, (e) puriﬁed KMO-12His (57 kDa) (bold arrow) eluted from
(indicated using arrows). (C) Cartoon illustrating the ﬂKMO-12His-FLAG construct. (For in
the web version of this article.)for 100 amino acids at the C-terminus of the expressed protein,
thus removing the mitochondrial outer membrane targeting signal.
This truncated protein was readily expressed in the soluble frac-
tion, was puriﬁed without difﬁculty and was identiﬁed as huKMO
by mass peptide ﬁngerprinting. However, this truncated protein
did not demonstrate production of 3-HK in the kinetic assay. Con-
current with these experiments, Hirai et al [15] reported that the
C-terminus of pig KMO has a dual role in that it is required for
enzymatic activity as well as membrane targetting. That group
showed that positions 30 to 50 from the C-terminus are neces-
sary for activity of the pig enzyme [15]. Our results corroborate
those of Hirai et al [15] as a corresponding C-terminal domaindetection, anti-FLAG M2 antibody and goat anti-mouse HRP secondary antibody, (a)
SDS-PAGE gel stained with simplyblue showing anti-FLAG conjugated protein A
, (b) ﬂowthrough proteins which did not bind to the beads, (c) ﬁrst magnetic bead
the beads by TEV protease has precipitated with two contaminant E. coli proteins
terpretation of the references to colour in this ﬁgure legend, the reader is referred to
Table 3
Identiﬁcation of co-eluting proteins. KMO-FLAG contaminant E. coli proteins identi-
ﬁed by mass peptide ﬁngerprinting and their corresponding Mwt and Mowse scores.
Protein ID Molecular weight (Da) Mowse score
Tryptophan synthase, beta subunit 43670 437
Putative GTP-binding protein 39930 340
Table 4
Summary of protein expression. Constructs used for bacterial expression of KMO
exhibited a variety of expression parameters.
Protein construct Expressed Soluble Active Yield
Full length KMO-6His Yes No Yes nd
Truncate KMO Yes Yes No nd
Full length KMO-12His-FLAG Yes Yes Yes 19%
nd, not determined.
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acids 386–486 of the human enzyme resulted in soluble protein
but loss of enzymatic activity. This result differs from the recently
reported yeast KMO crystal structure where a truncated 1-390 res-
idue yeast KMO was reported to demonstrate enzymatic activity.
Whilst alignments (not shown) conﬁrm that the active site of
KMO is conserved between yeast and human KMO, homology
between the two is fairly poor at approximately 33% identity.
The regions remaining in the human truncate reported here are
similar when compared to this yeast truncate, however, the human
construct is not active. This indicates that a domain which is crit-
ical for the retention of enzymatic activity in human KMO is absent
or not required for enzymatic activity in the yeast protein. Because
extension of a protein by FLAG tag fusion has been shown to
increase solubility and stabilize heterologously expressed proteins
[18], we adopted this technique. Generation of a FLAG-tagged
fusion protein vastly improved the solubility whilst retaining
activity. This agrees with, and may be explained by, the observa-
tions of Hirai et al [15] using pig KMO in which the C-terminal
FLAG tag weakened the positive charge and hydrophobicity
required for membrane targetting [15].Fig. 6. Kinetic characterisation of KMO. Steady state kinetics for ﬂKMO-6His and p
concentrations of kynurenine and NADPH are plotted versus 3-HK produced for each prot
using GraphPad Prism4 software.The FLAG tag epitopes of the huKMO fusion protein, being max-
imally hydrophilic [18], were sufﬁciently exposed to allow afﬁnity
puriﬁcation. NiNTA afﬁnity and anion exchange chromatography
techniques were attempted for puriﬁcation of full Length KMO-
12His-FLAG but these puriﬁcation systems were less successful,
possibly due to the inaccessibility of tags or aggregation. The stea-
dy state kinetic parameters obtained for each substrate for the
puriﬁed enzyme were comparable to those reported for the human
enzyme when expressed in mammalian cells [8]. Approximately
19% of the bacterially expressed enzyme was recovered during
puriﬁcation. This compares with 60% overall recovery of KMO
expressed in mammalian cells [8]. Following puriﬁcation, huKMO
precipitated with two contaminant E. coli proteins, identiﬁed by
MALDI-TOF as the beta subunit of tryptophan synthase and a puta-
tive GTP-binding protein. Tryptophan synthase catalyses the ﬁnal
two steps in the biosynthesis of tryptophan [19]. The enzyme
typically exists as an a–bb–a complex and a long hydrophobic
channel links each a and b active site [20]. The existence of this
hydrophobic channel within the enzymemay explain its co-elution
and potential interaction with KMO during puriﬁcation as the twouriﬁed KMO-12His (FLAG removed during puriﬁcation) at 37 C, pH 7. Starting
ein and data ﬁtted to the Michaelis–Menten equation (v = Vmax.[L-Kyn]/(Km+[L-Kyn])
K. Wilson et al. / Protein Expression and Puriﬁcation 95 (2014) 96–103 103hydrophobic molecules may form complexes of unknown stoichi-
ometry. Because increased KMO activity in bacteria might drive
increased expression of upstream enzymes to maintain substrate
levels and homeostasis, we tested whether native bacterial TRP-
synthase expression was increased. Semi-quantitative RT-PCR con-
ﬁrmed no increase in native TRP-synthase mRNA expression,
therefore, the co-elution was more likely to be due to complex for-
mation or binding rather than upregulation of protein expression.
Many GTP-binding proteins are located on or bind to the plasma
membrane of cells. The precise identity of the second co-precipi-
tant with KMO was not determined, since mass peptide ﬁnger-
printing techniques for protein identiﬁcation can be limited by
differential sensitivity of detection for individual peptides [21]. In
the paper of Hirai et al [15], removal of co-eluting cytochrome
b5 and monoamine oxidase subunit B abolished KMO enzymatic
activity and these proteins were shown to form protein-protein
complexes with pig KMO via tight hydrophobic interactions [15].
The bacterial cells used in our system do not express these pro-
teins. Partially-puriﬁed huKMO remained active in the absence of
these proteins, suggesting ﬁrstly that E. coli provides functional
analogues for cytochrome b5 and MAO-B, or maybe that under
our conditions cytochrome b5 and MOA-B are not necessary for
huKMO activity. It is plausible that interaction of KMO with tryp-
tophan synthase and the GTP-binding protein may be creating a
hydrophobic environment for KMO, thus permitting activity to be
retained after partial puriﬁcation and removal of the membranous
environment in which KMO activity is optimal.
This is the ﬁrst report of successful expression of active human
KMO enzyme in a bacterial expression system with speciﬁc fusion
protein constructs allowing partial puriﬁcation and further charac-
terisation of the human KMO enzyme. These insights together with
the newly reported yeast KMO structural information provide use-
ful information for future studies on this important therapeutic
target enzyme. However, it will be necessary to achieve improved
yields of the human enzyme to enable large scale in vitro screening
of potential KMO inhibitors and for the elucidation of the human
KMO crystal structure.Funding Information
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